Ixekizumab contains an active component as Ixekizumab. It is a prescription medication for certain inflammatory conditions, primarily moderate to severe plaque psoriasis and psoriatic arthritis. This medication belongs to a class of drugs called interleukin inhibitors. This medication has been shown to have a rapid onset of action, with noticeable improvements in skin symptoms and joint pain often seen within the first few weeks of treatment. Ixekizumab received initial FDA approval on March 22, 2016.

It is used in the treatment of plaque psoriasis and psoriatic arthritis. Severe plaque psoriasis is a chronic autoimmune skin condition characterized by thick, red, and scaly patches. At the same time, psoriatic arthritis is an inflammatory condition that affects the joints and is often associated with psoriasis.

To use Ixekizumab, follow the instructions provided by your healthcare provider or as indicated on the medication label. It is typically administered as an injection under the skin. The exact dosing and administration instructions may vary based on the specific condition being treated.

Ixekizumab, like any medication, can cause side effects. Common side effects include injection site reactions, upper respiratory tract infections, and headaches. Serious side effects may include infections, allergic reactions, inflammatory bowel disease (IBD) exacerbation or new-onset, hepatitis B virus (HBV) reactivation, and the potential for depression or suicidal thoughts.

Ixekizumab carries several important warnings. These include an increased risk of serious infections, including tuberculosis (TB), and the possibility of reactivating latent TB infection. Allergic reactions, such as anaphylaxis, have been reported, requiring immediate medical attention. The development or exacerbation of inflammatory bowel disease (IBD), including Crohn's disease or ulcerative colitis, is another potential risk. Hepatitis B virus (HBV) reactivation can occur in individuals with a current or previous HBV infection. Monitoring for malignancies, including skin cancers, is advised. There is also a caution regarding the potential for this medication to cause or worsen depression, suicidal thoughts, or other mood disorders.

Precautions should be taken when using ixekizumab. Before starting treatment, individuals should be screened for latent tuberculosis (TB) infection, and appropriate treatment should be initiated if necessary. Close monitoring for signs of infection, including serious or opportunistic infections, is advised throughout treatment. Allergic reactions, such as anaphylaxis, have been reported and may require immediate medical attention. Individuals with a history of inflammatory bowel disease (IBD) should be closely monitored for disease exacerbation or new-onset symptoms. Caution should also be exercised in individuals with a history of malignancies or those at increased risk, with regular skin examinations recommended. It is important to discuss these precautions with your healthcare provider and follow their guidance to ensure safe and effective use.

It is vital to approach using ixekizumab cautiously and adhere to necessary precautions. Before starting treatment, discuss any pre-existing conditions, including liver disease, and inform your healthcare provider of any medications you are currently taking to avoid potential drug interactions. Pregnant and breastfeeding women should consult a doctor before starting the treatment. Regular monitoring for signs of infection, allergic reactions, or the development of inflammatory bowel disease is crucial. Additionally, stay vigilant for symptoms of depression, suicidal thoughts, or mood disorders, and promptly seek medical attention. Take precautions to minimize the risk of exposure to live vaccines and consider individual factors, such as cardiovascular risk factors and prior history of malignancies.

1. Eli Lilly and Company, Electronic medicines compendium (EMC), [Revised on 25 May 2023] [Accessed on 17th June 2023], https://www.medicines.org.uk/emc/product/8199/pil#gref
2. Eli Lilly and Company, US Food and Drug Administration, [Revised on March 2021] [Accessed on 17th June 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125521s014lbl.pdf

The drug information on this page is different from medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.